Dr. Bolin’s research is in maternal determinants of cardiovascular disease in the fetus and offspring. This is an extension of his clinical practice as a pediatric and fetal cardiologist. In particular, Dr. Bolin is studying the role of altered bioenergetics in the etiology of hypertrophic cardiomyopathy following fetal exposure to maternal diabetes mellitus. Tens of thousands of infants of diabetic mothers are born every year in the US. Approximately one-quarter of these children are born with hypertrophic cardiomyopathy, a disease characterized by abnormal thickening of the heart’s pumping chambers. Unfortunately, a significant portion of children with hypertrophic cardiomyopathy die in the neonatal period.
The goal of Dr. Bolin’s translational research is to identify ways to target the mitochondrion for therapeutic intervention in infants of diabetic mothers with hypertrophic cardiomyopathy.
All patient satisfaction surveys are submitted by verified patients and families of Arkansas Children's. The star rating is an average of all responses to the provider-related questions by an independent patient satisfaction company. Responses are measured on a scale of 1 to 5 with 5 being the best score. The comments listed reflect the positive experiences submitted by patients and families through the survey process. The comments are not endorsed by and do not necessarily reflect the views or Arkansas Children's.
The Arkansas Children's Adult Congenital Heart Disease program provides assists in the transition of patients from pediatric CHD programs to ensure there is no lapse in care.
Every day at Arkansas Children’s Heart Institute, we strive for excellence, and our outcomes prove it. Under the direction of nationally renowned pediatric cardiothoracic surgeon Dr. Brian Reemtsen, the Heart Institute achieved a remarkable 100% surgical survival rate last year, including transplants.
Congenital heart defects are the most common of all birth defects, occurring at a rate of approximately eight cases per 1,000 live births.